Discontinuation/Dose Reduction of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers during Acute Decompensated Heart Failure in African-American Patients with Reduced Left-Ventricular Ejection Fraction | Zendy

Jesse Kane | Zendy; Joseph K. Kim | Zendy; Syed Haidry | Zendy; Louis Salciccioli | Zendy; Jason Lazar | Zendy

Open Access

Discontinuation/Dose Reduction of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers during Acute Decompensated Heart Failure in African-American Patients with Reduced Left-Ventricular Ejection Fraction

Author(s) -

Jesse Kane,

Joseph K. Kim,

Syed Haidry,

Louis Salciccioli,

Jason Lazar

Publication year - 2017

Publication title -

cardiology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.547

H-Index - 63

eISSN - 1421-9751

pISSN - 0008-6312

DOI - 10.1159/000457946

Subject(s) - medicine , ejection fraction , acute decompensated heart failure , discontinuation , furosemide , heart failure , cardiology , renal function , creatinine , angiotensin converting enzyme , angiotensin receptor , ace inhibitor , angiotensin ii , blood pressure

Patients with heart failure (HF) and reduced left-ventricular ejection fraction (LVEF) benefit from angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blocker (ARB) therapy. While dose reduction/discontinuation (r/d) of β-blockers (BB) and furosemide in acute decompensated HF (ADHF) worsen outcomes, data on ACEI/ARB are lacking.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research